INDIVIOR PHARMACEUTICALS, INC. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $358M | ↑+19.7% | $102M | ↑+385.7% | 22.6% |
| 2025-09-30 | $314M | ↑+2.3% | $42M | ↑+90.9% | 13.7% |
| 2025-06-30 | $302M | ↑+1.0% | $18M | ↑+118.6% | 23.8% |
| 2025-03-31 | $266M | ↓-6.3% | $47M | ↓-23.0% | 24.8% |
| 2024-12-31 | $299M | — | $21M | — | 15.4% |
| 2024-09-30 | $307M | — | $22M | — | 11.4% |
| 2024-06-30 | $299M | — | $-97M | — | -39.5% |
| 2024-03-31 | $284M | — | $61M | — | 26.4% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 11 quarters
margin trajectory tells the operating-leverage storyGo deeper
INDV Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyINDV Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics